STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics

STAT PlusBiotech Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics Inceptive focuses on building ‘reusable’ models for sequence-based drugs Manage alerts for this article Email this article Share this article By Brittany TrangJune 3, 2026 Health Tech Reporter Brittany Trang[email protected]Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01. Jakob Uszkoreit went from inventing the “T” in ChatGPT to putting the “AI” in Alnylam’s RNAi therapeutics. After over a dozen years at Google, where he’d co-authored the seminal “Attention is all you need” paper that laid the foundations for artificial intelligence models like GPT, Uszkoreit in 2021 left a job at Google Brain to start Inceptive Nucleics. The company is building “AI foundation models of life” — models that will hopefully learn so much about how biology operates that they will be reusable across many different tasks without having to be trained specifically to do them. Advertisement On Wednesday, Alnylam and Inceptive announced a new, three-year strategic collaboration worth up to $2 billion, with $30 million up front in cash and equity in the startup. The additional payments will be predicated on the co-discovered drugs achieving preclinical, regulatory, and commercial sales milestones. In 2025, Alnylam’s total revenues were $3.7 billion. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Brittany Trang Health Tech Reporter Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout June 3, 2026 STAT Plus: Legend Biotech emerged as a rare market winner Biotech June 2, 2026 STAT Plus: Longevity startup NewLimit raises $435 million ahead of first clinical trial Advertisement The Readout June 2, 2026 STAT Plus: Radiopharmaceutical shows promise in post-Pluvicto setting Biotech June 1, 2026 STAT Plus: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns Biotech June 1, 2026 STAT Plus: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways Subscriber Picks